PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
37.20
0.00 (0.00%)
As of 10:52AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close37.20
Open37.22
Bid37.28 x 9000
Ask37.29 x 4300
Day's Range37.15 - 37.35
52 Week Range30.90 - 37.35
Volume4,318,383
Avg. Volume15,526,825
Market Cap221.738B
Beta1.07
PE Ratio (TTM)22.98
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (3.44%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Apple Just Hit A Buy Point, Joining These 3 Dow Stocks
    Investor's Business Daily38 minutes ago

    Apple Just Hit A Buy Point, Joining These 3 Dow Stocks

    Apple rose above a buy point Monday from its newly formed flat base. Fellow Dow stocks Microsoft, Pfizer and Disney all cleared entries Friday, as did Lockheed Martin.

  • The 3 Best Dow Dividend Stocks for 2018
    Motley Fool3 hours ago

    The 3 Best Dow Dividend Stocks for 2018

    Look for these companies to lift the market in the coming year.

  • The 5 Best-Selling Drugs of 2017
    Motley Fool4 hours ago

    The 5 Best-Selling Drugs of 2017

    Autoimmune-disease and cancer drugs ruled yet again.

  • Forbes5 hours ago

    A New PARP Drug For Breast Cancer? I'm Thrilled!

    The paradigm for using chemo first to treat advanced breast cancer may change, as we gain experience with these new drugs.

  • 3 Top Stocks That Are Cash Cows
    Motley Fool23 hours ago

    3 Top Stocks That Are Cash Cows

    It's not just the cash. It's what these companies do with it that really matters.

  • Here's Why GlycoMimetics Could Become a Takeover Target
    Motley Foolyesterday

    Here's Why GlycoMimetics Could Become a Takeover Target

    A wholly owned cancer drug could eventually reshape an important indication, and a new sickle-cell disease drug could be heading to the FDA as soon as next year.

  • Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion
    Zacks3 days ago

    Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion

    The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.

  • Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations
    Zacks3 days ago

    Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

    Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.

  • Dow Stocks Lead Early Surge; Costco Gains, Top Railroad Sells Off
    Investor's Business Daily3 days ago

    Dow Stocks Lead Early Surge; Costco Gains, Top Railroad Sells Off

    The Dow hammered out an early lead Friday, as investors looked to the possible release of a reconciled GOP tax reform package later in the morning.

  • 24/7 Wall St.3 days ago

    Pfizer Headed for New High After FDA Nod for Joint Disease Treatment

    Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved its treatment for adult patients with active psoriatic arthritis.

  • Reuters4 days ago

    Pfizer's Xeljanz gets FDA nod as joint disease treatment

    U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease. Xeljanz was approved as a 5-mg dose taken twice daily and as an extended-release 11-mg dose taken once daily as a drug for patients with active psoriatic arthritis who have not responded to other treatments. Psoriatic arthritis, a form of arthritis that affects some people who have skin disease psoriasis, is characterized by symptoms such as joint pain, stiffness and swelling.

  • Barrons.com4 days ago

    Valeant: Down It Goes!

    Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.

  • Forbes4 days ago

    Pfizer's Bet On Oncology

    Pfizer’s Oncology segment accounts for less than 20% of the company’s value, according to our estimates. For many other major pharma companies, their oncology portfolios are larger contributors to their top lines, and Pfizer has been looking to capitalize on opportunities in the space.

  • Pfizer's Second Biosimilar of Remicade Receives FDA Approval
    Zacks4 days ago

    Pfizer's Second Biosimilar of Remicade Receives FDA Approval

    The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.

  • TheStreet.com4 days ago

    Teva Options Jump to Record Amid New CEO's Latest Bid for Turnaround

    Teva options now total more than Pfizer and Merck combined.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkey4 days ago

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Reuters5 days ago

    Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval

    The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer's Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn's disease and skin disorder plaque psoriasis, the drugmaker said. With the approval, Ixifi joins the ranks of other biosimilars that have claimed market share from Remicade, including Pfizer and Celltrion Inc's Inflectra launched in late 2016, and Renflexis, made by Merck & Co and South Korea's Samsung Bioepis Co Ltd.

  • This Biotech Stock Rocketed On Human Trials For New Cancer Drug
    Investor's Business Daily5 days ago

    This Biotech Stock Rocketed On Human Trials For New Cancer Drug

    Cellectis popped early Wednesday after it and Dow's Pfizer presented strong data for first in-human trials of a cancer therapy.

  • 24/7 Wall St.5 days ago

    Why Cellectis Is Winning Big With Its Pfizer Partnership

    Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.

  • 5 Biotech Buyout Candidates for 2018
    Motley Fool5 days ago

    5 Biotech Buyout Candidates for 2018

    The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.

  • Why 2017 Was a Year to Forget for Pfizer Inc.
    Motley Fool5 days ago

    Why 2017 Was a Year to Forget for Pfizer Inc.

    Pfizer's 2017 wasn't horrible. Just ho-hum.

  • Market Realist6 days ago

    What Analysts Recommend for Eli Lilly in December 2017

    In October 2017, Eli Lilly (LLY) and CureVac announced a global collaboration for immuneoncology research.

  • Spark Therapeutics Stock Plunges on Hemophilia Therapy Data
    Zacks6 days ago

    Spark Therapeutics Stock Plunges on Hemophilia Therapy Data

    Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.

  • 3 Dividend Stocks to Buy on Sale
    Motley Fool6 days ago

    3 Dividend Stocks to Buy on Sale

    It's hard to go wrong with high dividend yields, low earnings multiples, and solid long-term business prospects.

  • 3 Dividend Stocks Perfect for Retirees
    Motley Fool6 days ago

    3 Dividend Stocks Perfect for Retirees

    Step right up and collect your income!